20-mer oligonucleotide complementary to Akt mRNA

[email protected]
20-mer oligonucleotide complementary to Akt mRNA
Trade Name
Orphan Indication Glioblastoma
USA Market Approval USA
USA Designation Date 2004-12-08 00:00:00
Sponsor Rexahn Corporation;9620 Medical Center Drive;Rockville, Maryland, 20850
Related Access Program
Center Trials & Treatment – Glioblastoma by Gene Expression Profile Center Trials & Treatment – Glioblastoma Multiforme Northwest Biotherapeutics – Glioblastoma Multiforme Northwest Biotherapeutics – Glioblastoma Celldex Therapeutics – Recurrent GBM